Search
for
Sort by
Research 91–120 of 1000+
- Network pharmacology and in vivo experimental analysis for validating the antifibrotic potential of Punica granatum leaves against skin scleroderma: the role of oxidative stress, inflammation and TGF-β1/Snail 1/p-Smad 3 signaling pathway
- 566 Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Dermatologic Reactions to Targeted Therapy
- Abstract 18: Targeted epidermal ablation of EGFR causes local and systemic inflammation
- 176 Hair eruption initiates adverse events of EGFR-targeted cancer therapy
- EGFR signaling is required for regenerative proliferation in the cochlea: Conservation in birds and mammals
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Regulation of Semaphorin3A in the process of cutaneous wound healing
- Management of Toxicities of Targeted Therapies
- Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- Suppression of Wnt/β-catenin signaling by EGF receptor is required for hair follicle development
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
- EGFR Controls Hair Shaft Differentiation in a p53-Independent Manner
- Clinical-Exome Sequencing Unveils the Genetic Landscape of Polycystic Ovarian Syndrome (PCOS) Focusing on Lean and Obese Phenotypes: Implications for Cost-Effective Diagnosis and Personalized Treatment
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- EGFR: stopping stathmin to start the cycle
- The hair follicle enigma
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Roles of the Hedgehog Signaling Pathway in Epidermal and Hair Follicle Development, Homeostasis, and Cancer
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Differential activity of 2-methylene-19-nor vitamin D analogs on growth factor gene expression in rhino mouse skin and comparison to all-trans retinoic acid